𝗧𝗼𝗱𝗮𝘆, 𝗦𝗰𝗿𝗶𝗯𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗼𝗳𝗳𝗶𝗰𝗶𝗮𝗹𝗹𝘆 𝗯𝗲𝗰𝗮𝗺𝗲 𝗮 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹-𝘀𝘁𝗮𝗴𝗲 𝗯𝗶𝗼𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝗰𝗼𝗺𝗽𝗮𝗻𝘆 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗺𝗲𝗻𝘁 𝗼𝗳 𝗦𝗧𝗫-𝟭𝟭𝟱𝟬, a novel 𝘪𝘯 𝘷𝘪𝘷𝘰 epigenetic CRISPR therapy designed to deliver ultra-durable lowering of “bad cholesterol,” from a single dose, all without permanently altering the genome. This program is built on years of intentional and iterative engineering focused on improving the safety, specificity, potency, and durability of CRISPR medicines. 𝗕𝘂𝘁 𝘄𝗵𝗮𝘁 𝗲𝘅𝗰𝗶𝘁𝗲𝘀 𝗺𝗲 𝗺𝗼𝘀𝘁 𝗶𝘀 𝘄𝗵𝗮𝘁 𝘁𝗵𝗶𝘀 𝗰𝗼𝘂𝗹𝗱 𝗺𝗲𝗮𝗻 𝗳𝗼𝗿 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗹𝗶𝗸𝗲 𝗺𝘆𝘀𝗲𝗹𝗳. As someone at high risk of ASCVD, like roughly one-third of adults in the U.S., I’ve spent a lot of time thinking about the burden patients carry. For a chronic disease like ASCVD, prevention is far from easy. Success depends on maintaining near-perfect adherence to pills or injections for decades. In the real world, that’s incredibly difficult and simply not practical for most people. The fact that ASCVD remains the leading cause of death globally, despite plenty of therapeutic choices, makes that painfully clear. 𝗧𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝘀𝗵𝗼𝘂𝗹𝗱 𝗮𝘀𝗽𝗶𝗿𝗲 𝘁𝗼 𝗺𝗼𝗿𝗲 𝘁𝗵𝗮𝗻 𝗰𝗵𝗮𝗶𝗻𝗶𝗻𝗴 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝘁𝗼 𝗹𝗶𝗳𝗲𝗹𝗼𝗻𝗴 𝗺𝗲𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀. The vision behind STX-1150 is to provide year to decades of LDL-C lowering from a simple intervention, helping free patients from the constant burden of chronic treatment while more effectively reducing the risk of the world’s leading cause of death. The future is about empowering patients to take greater control of our own health destiny and preventing disease rather than waiting to treat it after catastrophe occurs. 𝗜 𝗯𝗲𝗹𝗶𝗲𝘃𝗲 𝗮 𝗻𝗲𝘄 𝗲𝗿𝗮 𝗼𝗳 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗶𝘀 𝗼𝗻 𝘁𝗵𝗲 𝗵𝗼𝗿𝗶𝘇𝗼𝗻, 𝗼𝗻𝗲 𝘄𝗵𝗲𝗿𝗲 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝗰𝗮𝗻 𝗱𝘂𝗿𝗮𝗯𝗹𝘆 𝗿𝗲𝘀𝗵𝗮𝗽𝗲 𝗹𝗼𝗻𝗴-𝘁𝗲𝗿𝗺 𝗵𝗲𝗮𝗹𝘁𝗵 𝗮𝗻𝗱 𝗮𝗹𝗹𝗼𝘄 𝘂𝘀 𝗮𝗹𝗹 𝘁𝗼 𝗹𝗶𝘃𝗲 𝗹𝗼𝗻𝗴𝗲𝗿, 𝗵𝗲𝗮𝗹𝘁𝗵𝗶𝗲𝗿 𝗹𝗶𝘃𝗲𝘀 𝘄𝗶𝘁𝗵 𝗴𝗿𝗲𝗮𝘁𝗲𝗿 𝗳𝗿𝗲𝗲𝗱𝗼𝗺. Extremely proud of the entire Scribe team for advancing this vision. Excited for what comes next.

Welcome to lesson #3 of 𝗦𝗰𝗿𝗶𝗯𝗲 𝗦𝘆𝗹𝗹𝗮𝗯𝘂𝘀, our educational series exploring how genetic medicine can tackle some of health’s most critical challenges. We previously covered the potential of genetic medicine to restore and improve everyone's health. In this post, we’ll go back in time to understand where CRISPR – one of the most powerful technologies for genetic medicine – came from and how it’s being used to develop breakthrough therapies today. Have a question or a topic we should cover in a future post? Drop it in the comments. 📖 𝗛𝗼𝘄 𝗖𝗥𝗜𝗦𝗣𝗥 𝘄𝗮𝘀 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝗲𝗱 Decades before CRISPR was harnessed into a gene editing technology, scientists understood that DNA holds the natural blueprint for disease prevention. The problem was turning that knowledge into safe, reliable treatments. They lacked a tool precise enough to make efficient, accurate edits to the human genome. The discovery of CRISPR closed that gap, and it all started with bacteria. For the full post, head over to our Substack where we cover: • The origin of CRISPR as a natural defense for bacteria to fend off viruses • How Jennifer Doudna (one of Scribe’s co-founders) and Emmanuelle Charpentier showed that CRISPR could be engineered and reprogrammed to target any piece of DNA, not just viral DNA • How CRISPR is being used today to improve human health across the globe 🔗 scribetx.substack.com/p/scri… ✍️ Image credit: IGI Glossary Icon Collection by Christine Liu of Two Photon Art for the Innovative Genomics Institute

Hear directly from our CEO @BenjaminLOakes about Scribe’s lead asset STX-1150, a clinical-stage epigenetic silencing therapy purpose-built to repress PCSK9, lower LDL cholesterol, and offer durable cardiovascular risk reduction to patients in need. More on our cardiometabolic pipeline, engineering approach compared to first-generation CRISPR technologies, and more in his conversation with @bradloncar. Full video is up on @BiotechTV: biotechtv.com/post/scribe-th…

Thanks to @bradloncar and @BiotechTV for the opportunity to discuss our approach and pipeline!

𝐇𝐂𝐖 𝟐𝟎𝟐𝟔: @scribetx which represents the next generation of CRISPR, had its IPO in July - the first clinical program targets PCSK9. With Co-Founder & CEO @BenjaminLOakes. $SCTX Full video: biotechtv.com/post/scribe-th…

👉 Atherosclerosis is complex. Its root cause is not. → Inflammation modifies the response. → Hypertension accelerates the damage. → Diabetes amplifies the risk. → Smoking fuels the process. 👆But without apoB-containing lipoproteins entering and being retained in the arterial wall, there is no atherosclerotic plaque. 👉LDL is not just another risk factor. It is the main causal driver of atherosclerosis. No cholesterol deposition. No plaque. @society_eas

Could not agree more!

🧬🔐 We built two-factor authentication into gene silencing. Read about it in our new blog and paper – links in the comments. We call this approach 𝗦𝗲𝗾𝘂𝗲𝗻𝘁𝗶𝗮𝗹 𝗣𝗿𝗼𝗼𝗳𝗿𝗲𝗮𝗱𝗶𝗻𝗴. It’s engineered into ELXR, the epigenetic silencing technology built on our CRISPR-CasX platform. The results? 𝗨𝗹𝘁𝗿𝗮-𝗹𝗼𝗻𝗴 𝗴𝗲𝗻𝗲 𝘀𝗶𝗹𝗲𝗻𝗰𝗶𝗻𝗴 𝘄𝗶𝘁𝗵𝗼𝘂𝘁 𝗰𝗵𝗮𝗻𝗴𝗶𝗻𝗴 𝗮𝗻𝘆 𝗗𝗡𝗔. → More than 10-fold greater specificity → More than 4-fold greater silencing activity across every target tested → No toxicity in stress tests, rescuing growth defects observed with Cas9-based silencers → Mechanism mirrors the cell’s natural regulation Learn more about this work led by Emeric J Charles, Christie C Sze, @BenjaminLOakes, Sarah Denny, @jdf_ev, and team below.

This week, don’t miss these upcoming talks by our co-founders: 1️⃣ Fireside chat with CEO @BenjaminLOakes at the @HCWCO 28th Annual Global Investment Conference. This will take place Tuesday, September 15 at 2:30 p.m. ET in New York. #HCWConference 2️⃣ Panel discussion where VP of External Innovation @BStaahl will discuss “Advances in Gene Editing” at the Cell & Gene Therapy Symposium. The session begins Thursday, September 17 at 11:00 a.m. PT in La Jolla and is hosted by the @CALifeSciences, @CIRMnews, and Gene Therapy Initiative at @UCSanDiego.

𝗧𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗶𝘀𝘁: 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗲𝘀 𝗧𝗵𝗮𝘁 𝗖𝗼𝘂𝗹𝗱 𝗥𝗲𝗱𝗲𝗳𝗶𝗻𝗲 𝗛𝘂𝗺𝗮𝗻𝗶𝘁𝘆 — 𝗼𝗿 𝗡𝗲𝘃𝗲𝗿 𝗙𝘂𝗹𝗹𝘆 𝗗𝗲𝗹𝗶𝘃𝗲𝗿 𝘍𝘶𝘴𝘪𝘰𝘯, 𝘢𝘥𝘷𝘢𝘯𝘤𝘦𝘥 𝘯𝘶𝘤𝘭𝘦𝘢𝘳, 𝘈𝘐, 𝘲𝘶𝘢𝘯𝘵𝘶𝘮 𝘵𝘦𝘤𝘩𝘯𝘰𝘭𝘰𝘨𝘪𝘦𝘴, 𝘣𝘪𝘰𝘮𝘦𝘥𝘪𝘤𝘪𝘯𝘦, 𝘢𝘯𝘥 𝘨𝘦𝘯𝘦𝘵𝘪𝘤 𝘦𝘯𝘨𝘪𝘯𝘦𝘦𝘳𝘪𝘯𝘨 Next week, our co-founder and CEO @BenjaminLOakes will discuss today’s most ambitious and promising technologies – including gene editing and silencing – at #IPAVision 2026, the Institute for Portfolio Alternatives’ premier event. Panel details below. 📅 Wednesday, September 16, 2026 🕗 5:15-6:05 p.m. ET 📍 Atlanta

This morning at the @WellsFargo Healthcare Conference, our co-founder and CEO @BenjaminLOakes will participate in a fireside chat. More information below 👇 📅 Wednesday, September 9, 2026 🕗 8:00 a.m. ET 📍 Boston

Epigenetic silencing made the @nytimes today. The real-world example for how it could improve heart health: Scribe’s single shot designed to reduce LDL cholesterol. Here’s how it works. While gene editing rewrites the DNA you were born with, our silencing approach changes how a gene behaves and leaves the code intact. Instead of a daily statin, a single dose of our epigenetic silencing therapy STX-1150 represses the PCSK9 gene in the liver that destroys the receptors your body uses to clear LDL-C, keeping the levels of this ‘bad’ cholesterol lowered for years and drastically lowering the risk of heart disease. STX-1150 is in clinical trials now. For more details, read the Times story and check out our website in the links below.

Welcome back to 𝗦𝗰𝗿𝗶𝗯𝗲 𝗦𝘆𝗹𝗹𝗮𝗯𝘂𝘀, where we explore how genetic medicine can tackle some of the most critical challenges in human health. Last time, we defined genetic medicine and discussed how it differs from traditional forms of treatment. In this lesson, we’ll dive into the many ways that this technology can be harnessed to improve health worldwide. 📖 𝗛𝗼𝘄 𝗚𝗲𝗻𝗲𝘁𝗶𝗰 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝗖𝗮𝗻 𝗥𝗲𝘀𝘁𝗼𝗿𝗲 𝗮𝗻𝗱 𝗜𝗺𝗽𝗿𝗼𝘃𝗲 𝗛𝗲𝗮𝗹𝘁𝗵 𝗳𝗼𝗿 𝗘𝘃𝗲𝗿𝘆𝗼𝗻𝗲 The goal of genetic medicine is to directly remedy the underlying biology of harmful disease to restore, improve, and extend healthy quality of life. Instead of managing symptoms and requiring daily medication like traditional drugs may, genetic medicine can prevent and even potentially cure disease before it strikes. The Human Genome Project, launched in 1990, laid the foundation of genetic medicine and gave us a roadmap to understand how our DNA can drive or prevent disease. In fact, some people are born with natural, lifelong protection from specific diseases written into their DNA. That's nature's blueprint, which genetic medicine aims to read and deliver to everyone. For the full post, head over to our Substack where we cover: • Why genetic medicine has so far been largely limited to rare, terminal diseases • An introduction to Victoria Gray, the first patient to be treated with CRISPR genetic medicine for sickle cell disease • Ongoing advances in CRISPR technology to support treatments for a much wider range of people and that are not only effective enough but also safe enough to address common diseases • Genetic medicine targeting the world’s leading cause of death: heart disease • Examples of genetic switches that can raise or lower cardiovascular risk 🔗 scribetx.substack.com/p/scri… 𝗨𝗽 𝗻𝗲𝘅𝘁: 𝗔 𝗱𝗲𝗲𝗽𝗲𝗿 𝗱𝗶𝘃𝗲 𝗶𝗻𝘁𝗼 𝗖𝗥𝗜𝗦𝗣𝗥-𝗯𝗮𝘀𝗲𝗱 𝗴𝗲𝗻𝗲𝘁𝗶𝗰 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀 In our next few posts, we’ll explore: 🧬 How CRISPR technology works 🧑‍🔬 CRISPR’s surprising origin story! 🛠️ Engineering CRISPR into different medicines and tools Let us know what other questions you’d like us to cover.

Today we reported our second quarter 2026 financial results and recent corporate highlights including: → Initiation of a first-in-human Phase 1 clinical trial for our in vivo epigenetic silencing therapy STX-1150 → @CIRMnews awards of more than $25M to advance our gene editing programs STX-1200 for Lp(a) lowering and STX-1400 for triglyceride lowering toward clinical entry → The latest manuscript on ELXR, our highly engineered epigenetic silencing technology → The completion of our IPO and funding into the first half of 2029 “The second quarter and the weeks immediately following represented a transformational period for Scribe,” said @BenjaminLOakes, Ph.D., co-founder and Chief Executive Officer of Scribe Therapeutics. “We advanced our lead silencing asset STX-1150 into the clinic, secured significant grant support from CIRM to develop our next two cardiometabolic assets, and successfully completed our initial public offering. These achievements position us to execute across a broadly differentiated portfolio of CRISPR genetic medicines designed to address the three major lipid drivers of atherosclerotic cardiovascular disease: LDL-C, Lp(a), and triglycerides.” Learn more in our press release: globenewswire.com/news-relea…

We’re holding Office Hours this week with Scribe co-founders, David Savage, @UCBerkeley professor, and @BenjaminLOakes! With Dr. Savage’s latest new research out investigating the precision of base editing, they sat down for a Q&A to break down the surprising findings and what they mean for building safer genetic medicines. They cover how this work reveals: 1️⃣ Base editors carry a different set of off-target risks. Where do those off-target effects occur, and how do they differ from what you'd see with a genome editor? 2️⃣ What’s surprising about the actual specificity and safety of base editors 3️⃣ Implications for research on genetic medicine approaches and the use of base editors and deaminase-based technologies in the clinic And more! Read the full interview here on Substack: scribetx.substack.com/p/q-an… New to our blog? Subscribe to stay updated on our educational content, scientific publications, and wider progress engineering purpose-built genetic medicines.

This fall, our management team will be participating in the following upcoming investor conferences. More details below and in our press release: globenewswire.com/news-relea… 📣 Wells Fargo Healthcare Conference @BenjaminLOakes, Ph.D., Co-founder and CEO, will participate in a fireside chat on Sept. 9, 2026 at 8:00 AM ET in Boston. 📣 H.C. Wainwright 28th Annual Global Investment Conference Benjamin Oakes, Ph.D., Co-founder and CEO, will present on Sept. 15, 2026 in New York. 📣 Cell & Gene Meeting on the Mesa David Parrot, M.B.A., CFO, will deliver an Innovation Spotlight presentation on Oct. 5, 2026 at 5:15 PM MT in Phoenix. @WellsFargo @HCWCO @alliancerm #CGMesa26

☝️If we continue to consider LDLc levels of 100–120 mg/dL “acceptable,” we should not be surprised to find atherosclerosis already present in young adults 👉LDLc levels above approximately 40–50 mg/dL are supraphysiological. Lifelong exposure to higher LDLc levels drives atherosclerosis, which eventually translates into clinical ASCVD events 👉And yet, ASCVD remains the #1 cause of death worldwide

The Golden Age of Discovery Has Begun 🇺🇸

Presented at #ESCCongress: Among 16,808 adults without known cardiovascular disease, silent atherosclerosis was present in 57.1%, was detectable in early adulthood, and became more prevalent and extensive with age in a sex-dependent pattern. Full REACT trial results: nej.md/46gp1hP @escardio